Cyprotex PLC (AIM: CRX) today announces the resignation of David Evans as a Non-executive Director of the Company with immediate effect and the appointment of John Dootson as Chief Financial Officer effective from 2 March 2009.
Commenting on the directorate changes, Steve Harris, Chairman of Cyprotex said: "David has made a significant contribution to the Company as a Non-executive Director and the Board would like to thank him for his contribution to the Company and wish him well with his future endeavours.
The Company is very pleased to appoint John Dootson as Chief Financial Officer. John has been associated with the Company for over four years as a consultant Financial Controller and therefore has intimate knowledge of the Company's business and finances. He brings to the Company wide ranging financial expertise gained in both industry and private practice."
Notes for Editors:
John Dootson, aged 47, has 25 years experience in both professional practice and in industry. Trained with Tenon and Ernst & Young, John has extensive managerial experience in major accounting practices and has worked on a wide range of projects including London Stock Exchange flotations and circulars, corporate governance, company acquisitions and disposals and specialist advice to growing SMEs. John has also worked in a number of roles in Industry at Financial Controller and Director level, including seven years within the senior head office finance team of BTP plc, a former FTSE250 specialty chemical manufacturer with over 50 sites worldwide prior to its sale to Clariant AG for 1.1bn GBP.
John is a Fellow of the Institute of Chartered Accountants in England and Wales and for the last four years he has assisted Cyprotex in a management consultative role that has included all aspects of finance and reporting.
The following information relating to Mr. Dootson is provided in compliance with the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies: